Silvia Christin Hellerud Rollefstad

Silvia Christin Hellerud Rollefstad serves as a Lecturer at the University of Oslo's Faculty of Medicine, specifically within the Department of Diakonhjemmet Research and Teaching. Her academic work focuses on the critical intersection of rheumatology and cardiovascular medicine, with particular emphasis on inflammatory joint diseases including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.

Dr. Rollefstad's research interests center on cardiovascular risk assessment and management in patients with inflammatory joint diseases. Her work examines the complex relationship between systemic inflammation and cardiovascular complications, investigating how traditional cardiovascular risk factors interact with disease-specific elements in rheumatological conditions. She has made significant contributions to understanding arterial stiffness, atherosclerosis development, and the effectiveness of statin therapy in these patient populations. Her research often employs large-scale registry studies and international collaborative audits to evaluate real-world cardiovascular risk management practices.

Analysis of her publication record reveals a consistent focus on cardiovascular outcomes across inflammatory joint diseases. Her work demonstrates how inflammatory processes accelerate atherosclerosis and increase cardiovascular risk, while also examining how standard cardiovascular prevention strategies perform in these complex patient populations. She has contributed significantly to understanding mortality patterns, treatment implementation gaps, and the specific cardiovascular challenges faced by patients with rheumatoid arthritis and related conditions.

Dr. Rollefstad has been involved in numerous international collaborations examining cardiovascular risk management across different healthcare systems. Her work frequently addresses implementation challenges in translating cardiovascular prevention guidelines into clinical practice for rheumatological patients. She has participated in studies evaluating the impact of smoking cessation, lipid management, and blood pressure control on disease activity and cardiovascular outcomes in inflammatory arthritis.